Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: yoshiike f. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Sonehara K, et al. Among authors: yoshiike f. Thorac Cancer. 2019 May;10(5):1078-1085. doi: 10.1111/1759-7714.13047. Epub 2019 Apr 20. Thorac Cancer. 2019. PMID: 31006178 Free PMC article.
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Furuta M, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Shimokawa M, Oizumi S. Ikezawa Y, et al. Among authors: yoshiike f. Cancer Sci. 2022 Jun;113(6):2109-2117. doi: 10.1111/cas.15361. Epub 2022 Apr 15. Cancer Sci. 2022. PMID: 35377496 Free PMC article.
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Goya H, Kuraishi H, Koyama S, Ichiyama T, Yoshiike F, Hirai K, Agatsuma T, Tateishi K, Kanda S, Yamamoto H, Kubo K, Koizumi T. Goya H, et al. Among authors: yoshiike f. Cancer Chemother Pharmacol. 2012 Nov;70(5):691-7. doi: 10.1007/s00280-012-1957-0. Epub 2012 Sep 1. Cancer Chemother Pharmacol. 2012. PMID: 22941346 Clinical Trial.
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Wada Y, Koyama S, Kuraishi H, Miyahara T, Yoshiike F, Agatsuma T, Yamamoto R, Ono Y, Suzuki T, Hachiya T, Gomi D, Tateishi K, Hanaoka M, Koizumi T. Wada Y, et al. Among authors: yoshiike f. Respir Investig. 2016 Nov;54(6):462-467. doi: 10.1016/j.resinv.2016.07.003. Epub 2016 Aug 25. Respir Investig. 2016. PMID: 27886858
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T, Wakatsuki Y, Kobayashi T, Sonehara K, Tateishi K, Yamamoto M, Masubuchi T, Yoshiike F, Hirai K, Hachiya T, Koizumi T. Fukushima T, et al. Among authors: yoshiike f. Cancer Chemother Pharmacol. 2018 Jun;81(6):1043-1050. doi: 10.1007/s00280-018-3573-0. Epub 2018 Apr 11. Cancer Chemother Pharmacol. 2018. PMID: 29644460 Clinical Trial.
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, Agatsuma T, Kato A, Takata M, Kanda S, Hanaoka M, Koizumi T. Araki T, et al. Among authors: yoshiike f. Thorac Cancer. 2022 Jul;13(14):2031-2040. doi: 10.1111/1759-7714.14484. Epub 2022 May 26. Thorac Cancer. 2022. PMID: 35616056 Free PMC article.
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study).
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, Kato A, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T. Araki T, et al. Among authors: yoshiike f. Transl Lung Cancer Res. 2023 Jun 30;12(6):1320-1327. doi: 10.21037/tlcr-23-12. Epub 2023 Jun 15. Transl Lung Cancer Res. 2023. PMID: 37425417 Free PMC article.
18 results